Please ensure Javascript is enabled for purposes of website accessibility

Why VistaGen Therapeutics Stock Is Soaring Today

By Keith Speights - Updated Feb 18, 2021 at 12:04PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

An analyst is very bullish about the biotech.

What happened

Shares of VistaGen Therapeutics (VTGN -5.41%) were soaring 22.1% as of 11:27 a.m. EST on Thursday. The big jump came after Jefferies analyst Andrew Tsai initiated coverage on the stock with a buy recommendation. Tsai also set a one-year price target of $6, nearly three times the price of VistaGen's shares at the market close on Wednesday.

So what

Wall Street analysts aren't always right with their recommendations and price targets. But it's a good idea to at least understand why they're bullish about a stock.

Thumb up on one hand and the other hand holding cash

Image source: Getty Images.

In this case, Tsai really likes the potential for VistaGen's lead pipeline candidate PH94B. It's a nasal spray that VistaGen is evaluating in phase 2 studies targeting multiple neurological disorders. The company has already reported positive data from one of those studies, with PH94B showing promise in treating acute social anxiety disorder.

There are still plenty of risks for PH94B and VistaGen's two other pipeline candidates. But Tsai isn't alone in his optimism about the biotech stock. The consensus price target among analysts covering VistaGen is more than double the current share price.

Now what

VistaGen has several potential catalysts on the way that could help it meet Tsai's aggressive target. The company plans to launch a pivotal late-stage study of PH94B this year in treating anxiety in adults. It also expects to kick off several phase 2 studies for the experimental drug in other conditions.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

VistaGen Therapeutics, Inc. Stock Quote
VistaGen Therapeutics, Inc.
$1.05 (-5.41%) $0.06

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/23/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.